Fig. 8From: CircNUP50 is a novel therapeutic target that promotes cisplatin resistance in ovarian cancer by modulating p53 ubiquitinationGraphical Abstract. Interference with circNUP50-regulated p53 ubiquitination reverses platinum resistance in ovarian cancer (OC), and synergistic co-delivery of si-circNUP50 and platinum using nanosystems can overcome platinum resistance in an OC tumour modelBack to article page